# Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies

> **NCT00356928** · PHASE1 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 14 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Donor T cells

## Key facts

- **NCT ID:** NCT00356928
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2018-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00356928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00356928, "Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00356928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*